Skip to content

09969.HK

InnoCare Pharma Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 11.25
−3.60%
Ask drillr

Year over year

Reported trailing growth

Revenue
+133.6%
EBITDA
+637.2%
EBIT
+628.9%
EPS
+615.6%
Free cash flow
+332.2%
Operating cash flow
+582.8%

Forward estimates

Based on analyst estimates

Revenue
-77.4%
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+54.3%
EBITDA
+225.5%
EBIT
+183.8%
Net income
+242.0%
EPS
+238.5%
Free cash flow
+129.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026